
MYNZ
Mainz Biomed
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MYNZ
Mainz Biomed N.V.
A molecular genetics diagnostic company specializing in the early detection of cancer
Robert Koch Strasse 50, 55129 Mainz, Germany
--
Mainz Biomed N.V. was incorporated in the Netherlands on March 8, 2021. The company is a molecular genetics cancer diagnostic company established in 2021 to acquire PharmGenomics GmbH with the aim of commercializing its product portfolio in Europe and the United States. The company focuses on the diagnostic side of the cancer industry. The company competes with other entities that develop and offer diagnostic tests to detect the presence of cancer. The company's core product is the CRC screening stool DNA test, and they are in the early stages of researching a similar test for pancreatic cancer.
Company Financials
EPS
MYNZ has released its 2023 Q4 earnings. EPS was reported at -0.25, versus the expected -0.32, beating expectations. The chart below visualizes how MYNZ has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MYNZ has released its 2023 Q4 earnings report, with revenue of 214.76K, reflecting a YoY change of 11.11%, and net profit of -5.18M, showing a YoY change of 36.70%. The Sankey diagram below clearly presents MYNZ's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available